David Slack

CEO at Impilo Therapeutics

Chair

David Slack is an industry veteran with over 30 years’ experience in public and private biotech as well as large pharmaceutical companies. He has been responsible for numerous company financings, strategic alliances, mergers and acquisitions, and other partnerships. He joined the Board of Impilo predecessor company, Cend Therapeutics, in October 2019 and was appointed President and CEO in June 2020. David oversaw the merger of Cend with Caladrius Biosciences to form Lisata Therapeutics in 2022 and served as President and Director of Lisata. He then co-founded Impilo Therapeutics to enable to nucleic acid-based medicine to effectively treat solid tumor cancers Previously, David served as co-founding Chief Business Officer at Viracta Therapeutics. David served as Vice President for Business Development at Ionis Pharmaceuticals and in senior management positions as Rhône-Poulenc Rorer, RPR Gencell and Aventis Pharmaceuticals.